Group items tagged

The Department of Health and Social Care (DHSC), led by Victoria Atkins MP and Maria Caulfield MP, has unveiled proposed updates to the NHS Constitution for England, aiming to fortify the principles of privacy, dignity, and safety for all patients. Martha's rule was prompted by a campaign led by the parents of 13-year-old Martha Mills who tragically succumbed to sepsis after staff at King's College Hospital failed to escalate her care to intensive care, despite her family's pleas regarding her worsening condition in 2021. Under the new guidance is the introduction of Martha's Rule, empowering patients to request intimate care from someone of the same biological sex ensuring that the distinct needs of men and women are recognized and addressed. Patients and their loved ones can exercise the right to "access to a rapid review from outside the care team if the patient is deteriorating." The consultation on the proposed updates is set to run for eight weeks, inviting feedback from patients, healthcare professionals, and stakeholders for a review

Haleon, the consumer healthcare giant behind brands like Sensodyne toothpaste and Advil painkillers, has announced plans to shut down its Maidenhead manufacturing site in the UK. This decision will impact 435 employees and comes as part of a broader strategic realignment of the company's global manufacturing operations according to BBC. The Maidenhead facility, which has been in operation for years, manufactures some of Haleon's most popular oral health products, including Sensodyne and Parodontax. However, following a comprehensive review of its manufacturing capabilities, the company has concluded that the site is no longer economically viable. In a statement issued by a spokesperson for Haleon, they stated, "Following a strategic review of our global manufacturing capabilities, we have determined that our Maidenhead site is no longer a viable option for the manufacture of our products."

The Pharmacists' Defence Association (PDA) has submitted evidence to the NHS Pay Review Body (PRB), emphasising on the recruitment and retention of NHS pharmacists. It has urged the PRB to help the NHS achieve two important objectives - ensuring that pharmacists can achieve well-rewarded and the service is viewed as an a ppealing alternative by student pharmacists. The PDA suggested that for the NHS to remain competitive, the PRB should focus its pay approach on employees within Bands 5-8 this year. It recognised that the last recommendation from the PRB was a "flat rate increase" and it left those working in the above-mentioned bands feeling "unhappy", which led to the CSP taking strike action over pay for the first time in their history.

HayMax, manufacturer of organic, drug-free allergen barrier balms for hay fever, dust, and pet allergies, has recently won the 2023 Global 100 awards. The HayMax balm, applied around nostril rims and eye bones, is an innovative allergen blocker against pollen, dust, and pet allergens entering the body. Independent university research confirms it traps over a third of pollen, along with dust mites and pet dander, before they enter the body, according to HayMax. The drug-free balm is Soil Association-certified organic, comprising 100 per cent natural ingredients. Safe for children, pregnant, and breastfeeding women, it holds the Vegetarian Society Approved trademark. This award has come as a complete surprise to us at HayMax," said HayMax MD, Max Wiseberg. "Being held in such high regard through this global recognition is truly delightful." "The Global 100 aims to offer readers insight into firms that excel in their chosen specialties, and the award underscores hard work and innovation of various companies," said its organisers.

HayMax, maker of the famous organic drug-free allergen barrier balm has been awarded the 'British Made Award' for Best British Allergy Product 2022. The award celebrates businesses that work tirelessly to make their region one of the most diverse and dynamic the UK has to offer. HayMax MD and creator Max Wiseberg comments: "This award means a great deal to us. We've always been proud that our products have been manufactured in the UK. We are passionate about reducing the cost to the environment so being British-made means we keep the miles down and reduce our carbon footprint." HayMax balms are manufactured in the UK. It buys local to reduce the cost to the environment, even if it means it costs a bit more. HayMax's current pots are now made in the UK, which has been great for reducing their carbon footprint. Its tins come from London. The new pots can be recycled and re-used. The brand has now switched to using sugar cane to make its pots and has also reduced the amount of material used in the pots by just over 54%. And they have switched from the plastic labels to paper labels.

The Mentholatum Company is shaking up the dry eye market with a clinically proven, world-leading advanced dry eye relief formulation. Rohto Dry Aid relieves EIGHT symptoms of dry eye and helps hydrate, protect and restore the tear film. Elvy Mardjono, senior brand manager for Rohto Dry Aid, says: "Rohto Dry Aid, with its Tearshield Technology™ acts fast, is non-blurry and delivers soothing relief for up to 12 hours." Rohto Dry Aid's Tearshield Technology™ formulation is kind to the eyes and designed to mimic the properties of the natural tear film, providing the protection and hydration required to tackle dry spots and restore all layers of the natural tear film.

The Serious Shortage Protocol (SSP), for Estradot 50mcg patches will expire at 23.59pm on Friday 24 February 2023. Department of Health and Social Care (DHSC) has confirmed that sufficient stock of Estradot 50mcg patches are now available to meet normal demand. "After 24th February, any prescriptions for Estradot 50mcg patches must be dispensed in accordance with the prescription, and SSP048 will no longer be valid for use," said DHSC. Top tips for SSP claims by PSNC: Where available, use the claim amend facility on the PMR system to rectify any incorrect EPS claims already submitted this month. For any supplies made in accordance with SSPs, check that the correct number of patient charges are collected and declared on the end of month FP34C submission. NHSBSA advise that contractors must follow the specific endorsement guidance issued with each SSP and endorsements should be clear and unambiguous - NHSBSA processing staff must be able to determine what has been supplied. NHSBSA have published information on common SSP endorsing errors they see when processing claims.

The Department of Health and Social Care (DHSC) has created a new NIHR Research Delivery Network (RDN) to support the successful delivery of health and social care research in England. The network, which will start operating from next year, will play a critical and active role in implementing government policies. It will support in implementing the Life Sciences Vision, the Future of UK Clinical Research Delivery vision, and policy for life sciences research and development. The new network would be mainly working on growing the amount of commercial clinical research as its key strategic ambition. Also, NIHR RDN will be responding to the findings of the Lord O'Shaughnessy review, which set out a clear blueprint for how the UK can return to its global leadership role.

AstraZeneca UK has revised the expiry dates for certain batches of Fluenz Tetra nasal spray vaccines as a precautionary measure, after finding that their potency (strength) dropped faster than predicted once thawed, during routine testing. The Medicines and Healthcare products Regulatory Agency (MHRA) has been informed by the manufacturer that the printed expiry date for a limited number of batches is "incorrect." However, the MHRA has assured patients that the affected batches are safe to use and fully effective within the amended expiry date. If the vaccine is administered after the amended expiry date, it may be less effective in protecting against flu, it said. The UK regulatory authority also reiterated that it "keeps the safety of medicines, including vaccines, under review, and acts where necessary to protect patients and the public."

London's Great Ormond Street Hospital and Alder Hey Children's Hospital in Liverpool are poised to introduce groundbreaking gender-related services in England, following the closure of the Gender Identity Development Service (Gids) operated by the Tavistock and Portman NHS Foundation Trust. Amid concerns expressed by hospital executives regarding the closure of Gids, with leaked emails revealing apprehensions about appointment cancellations and inadequate communication with the new services, the National Health Services England (NHSE) has confirmed "its commitment to ensuring continuity of care for patients already accessing endocrine care in GIDS." NHSE's decision to transition to regional services stems from a 2022 interim review, led by Dr. Hilary Cass, which highlighted the need for improved support structures for gender-distressed youth. It emphasized a significant increase in referrals to Gids, surpassing 5,000 in 2021/22, compared to less than 250 a decade ago.

The UK Health Security Agency's (UKHSA) Chief Executive, Professor Dame Jenny Harries has expressed concern that measles outbreak could spread to other towns and cities unless urgent action is taken to increase Measles, Mumps and Rubella (MMR) vaccination uptake in areas at greatest risk. The virus can spread very easily among those who are unvaccinated, especially in nurseries and schools, she said on Friday (19 January) during a visit to irmingham to review the ongoing work to contain the spread of the disease. A rapid rise in cases has been seen in the West Midlands since 1 October 2023, with 216 confirmed cases and 103 probable cases recorded till 18 January. The majority of the cases (around 80 per cent) were reported from Birmingham, with about 10 per cent in Coventry, mostly affecting children aged under 10 years. Dame Jenny is calling on all local areas to increase MMR vaccine uptake rates in communities across the country.

In a significant move to enhance the working conditions of over 50,000 postgraduate doctors in the National Health Service, NHS England has unveiled a series of measures aimed at providing greater choice and opportunities to the new entrants in the medical profession. With flexible rotas, reducing payroll errors, and easing the financial burden of course fees, the NHS has taken steps to address the issues faced by junior doctors in order to support their well-being. In recent announcement, 83 per cent of senior doctors and dentists accepted the government's pay offer. Alongside the junior doctors who still fighting for fair pay and recognition, the senior medical professionals demanded that the authorities help them tackle issues pertaining underfunding and overworking in the NHS. Junior doctors in training also often face challenges with frequent moves between trusts, leading to short notice changes in work schedules and duplicated inductions when transitioning to new hospitals. As a measure taken by the health serivces, the committee aims to review the minimum legal requirements for statutory and mandatory training, potentially halving the time burden for such training and allowing doctors to spend more time caring for patients as part of the long-term workforce plan.

NHS England has confirmed the initial sites that will test and implement Martha's Rule in the first phase of the programme. This follows the announcement in February regarding NHSE funding for the major patient safety initiative for this financial year. The scheme is named after Martha Mills, who died from sepsis at the age of 13 in 2021. She had been treated at King's College Hospital, London, where a failure to escalate her to intensive care and a lack of response to her family's concerns about her deteriorating condition contributed to her death. Martha's Rule aims to provide a consistent and understandable way for patients and families to seek an urgent review if their or their loved one's condition deteriorates and they are concerned this is not being responded to. NHS England on Monday (27 May) announced that the scheme will be implemented at 143 hospital sites across the country by March 2025.

When faced with the unfortunate situation of medical malpractice, it's understandable that you may feel overwhelmed and uncertain about the next steps. One crucial aspect that often gets overlooked in the turmoil is the importance of timely filing a medical malpractice claim. Delaying this process can have significant negative consequences on your ability to secure justice and compensation. Here's why you shouldn't delay in filing a medical malpractice claim. A Crucial Step in Seeking Justice When faced with legal challenges, finding the right lawyer is paramount. Your choice of legal representation can significantly impact the outcome of your case and your overall experience throughout the legal process. Begin by identifying lawyers with expertise in your specific legal issue, whether it's personal injury, family law, or business disputes. Conduct thorough research, read client reviews, and seek recommendations from trusted sources to narrow down your options. Meet with potential attorneys for consultations to assess their experience, communication style, and commitment to your case. Whether you are looking for a Scranton Medical Malpractice Lawyer or in any other place, look for a lawyer who not only has the necessary skills and knowledge but also demonstrates empathy, transparency, and a genuine dedication to advocating for your rights. By investing time and effort into finding the right lawyer, you set the foundation for a strong legal strategy and increase your chances of a favorable resolution.

Healthcare professionals in the UK are being advised to avoid prescribing the migraine and antiseizure medication topiramate, commonly known by the brand name Topamax, to women and girls unless they fulfil the requirements of a Pregnancy Prevention Programme. This guidance follows new safety measures introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) following a major safety review, which highlighted a potential increased risk of neurodevelopmental disabilities in children exposed to topiramate during pregnancy. The Commission on Human Medicines (CHM) evaluated studies that examined the risks associated with using topiramate during pregnancy. These studies indicated that children born to mothers who took topiramate during pregnancy had an approximately 2 to 3 times higher risk of intellectual disability, autism spectrum disorders, and attention deficit hyperactivity disorder. Based on CHM's recommendations, the MHRA now advises that topiramate should not be prescribed for treating epilepsy during pregnancy unless there is no suitable alternative.

We've all heard of Dry January, but that doesn't mean that the first month of the year is the only one where you can quit the booze for an intermittent period. No, you can do it anytime and often it can be just the push you need to review your relationship with the hard stuff. More and more of us are developing problematic relationships with alcohol, and the likes of addiction are on the rise. Attempting an alcohol detox can be a good way to understand your relationship, although if you are heavily reliant on the substance, it is worth doing it in a controlled and safe environment with professional care. That said, for many of us that isn't the case and giving up for a month can see a wealth of changes in your life. So, what can you expect exactly? Improved Physical Health First and foremost, your physical health will improve as a result. Alcohol is known for its empty calories and sugar. It's why many of us develop beer bellys and gain weight when we drink regularly. Ultimately, by cutting those calories, you'll find it much easier to shed weight and the results can happen relatively quickly. What's more, as alcohol slows down metabolism and can often lead to poor food choices like takeaways, eliminating it makes it much easier to manage your weight.

Most people in Great Britain believe that new junior doctors, nurses and health care assistants are underpaid, senior doctors and matrons are paid about right, and NHS CEOs are paid too much, according to a new study. About half the people surveyed indicated that newly qualified junior doctors are paid too little, with this sentiment increasing to three in five (60 per cent) among Labour voters. The research conducted by the Policy Institute at King's College London, King's Business School, and Ipsos also showed that more people believe NHS staff overall were badly paid than well paid. Dr Nick Krachler, senior lecturer in Human Resource Management at King's Business School, said: "Our survey shows considerable alignment between public perception of NHS pay levels and the claims of trade unions and professional associations that pay levels - which are determined by government after consultation from a Pay Review Body - ​are unsatisfactory for frontline NHS roles." He highlighted the urgent need to address healthcare workers' economic wellbeing, hoping that the new government will consider it in its upcoming negotiations with junior doctors this week.

Nexium Control, the UK's number one selling heartburn product for 24-hour protection1, has commissioned research to explore consumer attitudes to heartburn awareness of the different products on the market in Great Britain and Ireland (1,500 UK and 500 IE respondents). The research found that 53% of respondents usually opt for short-acting treatments to heartburn2, despite longer-acting products being able to provide relief over a 24-hour period. The research from Nexium Control revealed that 54% of people surveyed wished there was a product that managed symptoms for longer3, with 55% of respondents agreeing that short-acting treatments only last a maximum of five hours4. To help their patients understand there are longer-acting options available, pharmacists can provide information and guidance on treatments, such as proton pump inhibitors like Nexium Control. Shorter-acting products, which shoppers often reach for, work by either neutralising the acid already in the stomach or by forming a layer that floats to the top of the stomach, stopping acid rising into the food pipe. Double action treatments which utilise both methods are also available. Containing esomeprazole, Nexium Control reduces the production of stomach acid for up to 24-hour protection with just one pill, treating the cause and symptoms of heartburn - allowing time for the oesophagus to recover from the acid irritation.

The latest NHS data showed that 487,432 individuals in England were diagnosed with dementia in June, the highest since the start of the pandemic. Although dementia diagnosis rates have reached 65 per cent, the NHS still aims to meet its target of diagnosing 66.7 per cent of the estimated total number of people living with a form of the disease. NHS stated that their staff across the country are actively assessing care home residents to identify more individuals who may have dementia. Dr. Jeremy Isaacs, National Clinical Director for Dementia at NHS England, praised the efforts of NHS staff in increasing diagnosis rates but acknowledged that more work is needed. "Getting a diagnosis of dementia is the first step in supporting people, with a wide range of NHS services able to help.